Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin's lymphoma: A case report

We describe a case of coronavirus disease 2019 (COVID-19) in a patient with mixed cellularity classical Hodgkin lymphoma (cHL) undergoing brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) therapy. A 43-year-old man presented to our hospital with a complaint of fever, for which h...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujii, Hiroyuki, Tsuji, Taisuke, Sugitani, Mio, Matsumoto, Yosuke, Yuba, Tatsuya, Tanaka, Shunya, Suga, Yoshifumi, Matsuyama, Aosa, Goda, Shiho, Omura, Ayaka, Shiotsu, Shinsuke, Takumi, Chieko, Ono, Seiko, Hiraoka, Noriya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988448/
https://www.ncbi.nlm.nih.gov/pubmed/33810911
http://dx.doi.org/10.1016/j.currproblcancer.2021.100739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988448/
https://www.ncbi.nlm.nih.gov/pubmed/33810911
http://dx.doi.org/10.1016/j.currproblcancer.2021.100739

Ejemplares similares